title: Chitooligosaccharides promote peripheral nerve regeneration in a rabbit common peroneal nerve crush injury model.
abstract: Chitooligosaccharides (COSs) are the biodegradation products of chitosan that have been demonstrated with neuroaffinity and/or neuroprotective actions. In this study, we investigated the possible benefits of treatment with COSs on nerve regeneration after crush injuries to peripheral nerves. The rabbits with the crushed common peroneal nerve were treated by daily intravenous injection of 1.5 or 3 mg/kg body weight of COSs or identical volume of saline (as the control) for a 6-week period. At the end of COSs treatment, electrophysiological assessments, Meyer's trichrome and Masson trichrome staining, and transmission electron microscopy were used to evaluate the regeneration of injured common peroneal nerve and atrophy of the tibialis posterior muscle. The results showed that the compound muscle action potentials, the number of regenerated myelinated nerve fibers, the thickness of regenerated myelin sheaths, and the cross-sectional area of tibialis posterior muscle fibers were significantly improved in the nerves that received COSs treatment and the results with COSs treatment displayed a dose-dependent pattern. This study demonstrated that COSs accelerated peripheral nerve regeneration after crush injury to rabbit common peroneal nerves. The COSs could probably become a potential neuroprotective agent for improvement of peripheral nerve regeneration after the injury and deserve for further studies.
authors: Jiangsu Key Laboratory of Neuroregeneration, Nantong University, Nantong, JS 226001, People's Republic of China.
authors: Yanpei
authors: Y
authors: Gong
authors: Leilei
authors: L
authors: Gong
authors: Xiaosong
authors: X
authors: Gu
authors: Fei
authors: F
authors: Ding
mesh_terms: D000818:Animals; D048271:Chitosan / Q000378:metabolism / Q000627:therapeutic use*; D004195:Disease Models, Animal; D009409:Nerve Crush; D009416:Nerve Regeneration / Q000187:drug effects*; D018696:Neuroprotective Agents / Q000627:therapeutic use*; D009844:Oligosaccharides / Q000627:therapeutic use*; D010525:Peripheral Nerves / Q000187:drug effects / Q000502:physiology*; D011817:Rabbits; D011897:Random Allocation; D020127:Recovery of Function / Q000187:drug effects; D012584:Sciatic Nerve / Q000187:drug effects / Q000293:injuries / Q000473:pathology
chemical_list: D018696:Neuroprotective Agents; D009844:Oligosaccharides; D048271:Chitosan